This week's top stories in cardiology:   FDA Panel: Continue using paclitaxel-eluting PAD Devices, with caveats.   Although the benefits of the devices were clear, the panel felt there should be a label change to warn of the late mortality signal seen in a key meta-analysis.   Many cardiac cath, electrophysiology lab directors receive big industry payments These payments were substantially higher than those made to local interventional cardiologists and electrophysiologist.    Two trials support shorter DAPT DAPT with a twist: Continuing the P2Y12 inhibitor instead of aspirin.    Do black patients with type 2 diabetes gain cardiac benefit from the SGLT2 and GLP-1 drugs? New findings suggest there is no effect on cardiovascular outcomes, although the analysis has limitations  

Continue using paclitaxel-eluting PAD devices

MDedge Cardiocast is the weekly podcast from Cardiology News. The information in this podcast is provided for informational and educational purposes only.

Medicine

Science & Medicine

Science

Health & Fitness

Life Sciences

 ISCHEMIA trial hailed as practice changing The largest-ever RCT of initial invasive versus conservative management of stable ischemic heart disease makes waves.  DAPA-HF: Dapagliflozin’s HFrEF efficacy confirmed in nondiabetics Further analyses from the DAPA-HF trial showed dapagliflozin cut death and heart failure events in HFrEF patients with no diabetes.  Colchicine cut post-MI CVD events Colchicine fulfilled the promise first seem in CANTOS that anti-inflammatory treatment can reduce cardiovascular disease events.  Getting high heightens stroke, arrhythmia risks Cannabis use or abuse among the young was associated with adverse cardiovascular consequences in two studies. Editor's note: This is the final episode of the MDedge Cardiocast. On behalf of Dr. Jim Dwyer and all of us at MDedge, thank you for supporting Cardiocast. For more MDedge podcasts, go to www.mdedge.com/podcasts.  Email the show: podcasts@mdedge.com Interact with us on Twitter: @MDedgeTweets

Vascepa gains event-reduction nod; diabetes ups ischemic risks

 Women have fewer cardiovascular events after non–ST-segment elevation ACS But they also remain undertreated with guideline-directed therapies. *  *  *   Help us make this podcast better! Please take our short listener survey: https://www.surveymonkey.com/r/podcastsurveyOct2019 *  *  *    FDA panel rejects vernakalant bid for AFib cardioversion indication Eleven years after the first attempt of the antiarrhythmic agent, the FDA panel voted resoundingly against approval.  Bariatric surgery tied to fewer cerebrovascular events The incidence of cerebrovascular events was 65% lower in obese people who underwent bariatric surgery compared with those without surgery  Intensive BP control cut dementia but increased brain atrophy and hurt cognitionThe small but significant ill effects worried some researchers at the Clinical Trials on Alzheimer's Disease conference. *  *  *   For more MDedge Podcasts, go to mdedge.com/podcasts Email the show: podcasts@mdedge.com Interact with us on Twitter: @MDedgeTweets

Post-STEMI events less likely in women; bariatric surgery may lower stroke risk

 Icosapent ethyl cost effective in REDUCE-IT analysis Treatment with the fish-derived drug Vascepa for CV event reduction is more effective and less costly than placebo. *  *  *   Help us make this podcast better! Please take our short listener survey: https://www.surveymonkey.com/r/podcastsurveyOct2019 *  *  *    DAPA-HF: Dapagliflozin benefits regardless of age, HF severity The SGLT2 inhibitor had similar efficacy in the elderly and across the spectrum of baseline symptom status.  Colchicine cut post-MI CVD events Colchicine fulfilled the promise first seem in CANTOS that anti-inflammatory treatment can reduce cardiovascular disease events.  Cardiac arrests peak with pollution in Japan The incidence of out-of-hospital cardiac arrests in Japan increased on days when counts of particulate matter spiked from the day before. *  *  *   For more MDedge Podcasts, go to mdedge.com/podcasts Email the show: podcasts@mdedge.com Interact with us on Twitter: @MDedgeTweets

New trick for old drug; Vascepa cost effective for CV reduction

This week’s Cardiocast is devoted entirely to Card Talk with cardiologist brothers Jim and Jerry Dwyer. They welcome two structural interventionalists at the Structural Heart and Valve Center at Emory Healthcare,  Kendra J. Grubb, MD, and  Isida Byku, MD. Both followed a unique track, training in both cardiac surgery and interventional cardiology and practicing in the fast-moving field of structural heart disease. *  *  *   Help us make this podcast better! Please take our short listener survey: https://www.surveymonkey.com/r/podcastsurveyOct2019 *  *  *   From the “picture that went around the world” of an all-female transcatheter aortic valve replacement team at Emory to advances in structural heart disease treatment, this interview includes expanding TAVR beyond the aortic valve and interventional heart failure treatment using “hooks and anchors and pulleys” to reshape the heart. Dr. Grubb is assistant professor in surgery and medicine at Emory University in Atlanta and surgical director of the Structural Heart and Valve Center at Emory Healthcare. On Twitter @KendraGrubb. She is an adviser, consultant, and/or speaker for Boston Scientific, Edwards, and Medtronic. She is also a principal investigator in Medtronic’s Optimize PRO trial and Ancora’s CorCinch PMVI studies. Dr. Isida Byku is an assistant professor at Emory University. On Twitter @IsidaByku. She has no disclosures.  *  *  *   For more MDedge Podcasts, go to mdedge.com/podcasts Email the show: podcasts@mdedge.com Interact with us on Twitter: @MDedgeTweets

Continue using paclitaxel-eluting PAD devices

Download our free app to listen on your phone